Form 4: Phio Pharma Director Receives Equity Grant

Phio Pharmaceuticals director Curtis Lockshin was granted 16,200 restricted stock units, vesting in one year, as reported in a recent SEC filing.

Summary

• Curtis Lockshin, a director of Phio Pharmaceuticals Corp., received a grant of 16,200 shares of common stock on September 11, 2025.
• These shares represent restricted stock units (RSUs) that are scheduled to vest on the first annual anniversary of the grant date.
• The acquisition price for these shares was $0, indicating they were granted as compensation.
• Following this transaction, Lockshin beneficially owns 18,555 shares of common stock, which includes shares underlying unvested restricted stock units.
• The reported number of securities has been adjusted to reflect prior reverse stock splits.
• A Section 16 Power of Attorney was executed by Curtis A. Lockshin on September 4, 2025, appointing Lisa C. Carson of Phio Pharmaceuticals Corp. and Irina Abbas of Hogan Lovells US LLP as attorneys-in-fact.
• These attorneys-in-fact are authorized to prepare, execute, and file SEC documents, including Forms 3, 4, 5, Schedules 13D, 13G, and Forms 144, on behalf of Lockshin.

Sentiment

Score: 7

Explanation: The grant of equity to a director is a positive sign of alignment and retention, contributing to stable corporate governance. However, the mention of prior reverse stock splits suggests the company has faced past challenges, which this routine grant does not fundamentally alter.

Positives

• Director Curtis Lockshin received a grant of 16,200 restricted stock units, which aligns his interests with those of shareholders by increasing his equity stake in the company.
• The establishment of a Power of Attorney streamlines the director's compliance with SEC reporting requirements, ensuring timely and accurate filings.

Future Outlook

The 16,200 restricted stock units granted to Director Curtis Lockshin are scheduled to vest on the first annual anniversary of the grant date, indicating future equity ownership and continued alignment of interests.

Industry Context

Equity grants, such as restricted stock units, are a standard component of director compensation packages in the biotechnology and pharmaceutical industries, aiming to align the interests of directors with those of shareholders. The mention of prior reverse stock splits suggests the company may have faced challenges with its share price, a common occurrence for smaller biotech firms navigating clinical development and market capitalization requirements.

Comparison to Industry Standards

• The grant of restricted stock units to a director is a common practice in publicly traded companies, particularly in the biotech sector, to incentivize long-term commitment and performance.
• The $0 price for the acquired shares is typical for equity compensation grants, distinguishing them from open market purchases.
• The vesting schedule of one year for RSUs is within the typical range for director equity awards, which can vary from immediate vesting to multi-year schedules.

Corporate Governance

Related Party Transactions

• Grant of 16,200 restricted stock units to Curtis Lockshin, a director of Phio Pharmaceuticals Corp., as part of his compensation package.

Stakeholder Impact

• Shareholders: The equity grant further aligns the director's financial interests with those of shareholders, potentially fostering long-term value creation.
• Management: The Power of Attorney simplifies the administrative burden for the director regarding SEC compliance.

Next Steps

• Vesting of 16,200 restricted stock units on the first annual anniversary of the grant (approximately September 11, 2026).

Key Dates

Recommendation

The filing reports a routine equity grant to a director and a power of attorney for SEC filings. While the equity grant aligns director interests, it does not present new material information that would significantly alter the company's fundamental outlook or warrant a change in investment stance. The mention of prior reverse stock splits suggests past challenges, which a single RSU grant does not fully offset.

Keywords

Phio Pharmaceuticals, PHIO, Curtis Lockshin, Director, Restricted Stock Units, RSU, Equity Grant, Insider Trading, Form 4, SEC Filing, Beneficial Ownership, Corporate Governance, Power of Attorney